Table 4, Strengths and Limitations of Systematic Review Using AMSTAR 29 - Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency

Strengths	Limitations
Kelly et al. (2013) ¹²
Stated the aim of the review, as well as the population, interventions, and outcomes of interest Does not appear to have restricted to randomized-controlled trials, as non-randomized studies and case reports have been included Searched the previous 20 years, and the report was published approximately 2 years after the last search date Provided their search terms and strategy Reported authors’ conflicts of interest and financial support	Did not explicitly state that the review methods were published before the conduct of the review Assessed 1 database, and does not report if they checked published reviews specialized registrars, or grey literature, or if they contacted experts in the field Search was restricted to articles in English, and authors did not provide a justification for this restriction Unclear if 2 review authors performed screening, study selection, and/or data extraction; no statement that these were done in duplicate A list of excluded studies and reasons for exclusion were not provided Included studies were not described in detail Risk of bias was not assessed Sources of funding for the studies was not reported, which may have influenced the studies’ reporting Potential causes of heterogeneity across the studies were not discussed, though this may have been because no adverse events were reported for any identified studies

Strengths

Limitations

Kelly et al. (2013) ¹²

Stated the aim of the review, as well as the population, interventions, and outcomes of interest
Does not appear to have restricted to randomized-controlled trials, as non-randomized studies and case reports have been included
Searched the previous 20 years, and the report was published approximately 2 years after the last search date
Provided their search terms and strategy
Reported authors’ conflicts of interest and financial support

Did not explicitly state that the review methods were published before the conduct of the review
Assessed 1 database, and does not report if they checked published reviews specialized registrars, or grey literature, or if they contacted experts in the field
Search was restricted to articles in English, and authors did not provide a justification for this restriction
Unclear if 2 review authors performed screening, study selection, and/or data extraction; no statement that these were done in duplicate
A list of excluded studies and reasons for exclusion were not provided
Included studies were not described in detail
Risk of bias was not assessed
Sources of funding for the studies was not reported, which may have influenced the studies’ reporting
Potential causes of heterogeneity across the studies were not discussed, though this may have been because no adverse events were reported for any identified studies

From: Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency

Cover of Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency

Raltitrexed in Patients With Dihydropyrimidine Dehydrogenase Deficiency: Rapid Review [Internet].

Vu T, Spry C; Authors.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 4Strengths and Limitations of Systematic Review Using AMSTAR 29

Table 4Strengths and Limitations of Systematic Review Using AMSTAR 2⁹